2017 Focused Update on Management of Valvular Heart Disease

These guidelines touch upon infective endocarditis, treatment of aortic stenosis and of primary and secondary mitral regurgitation, and direct-acting oral anticoagulants, among other topics.

Sponsoring Organizations: American Heart Association and American College of Cardiology

Target Audience: Primary care providers and cardiologists (both general and subspecialists) who treat patients with valvular heart disease (VHD)

Target Population: Adults with VHD

Background and Objective

Since the 2014 publication of the last comprehensive guideline on VHD (NEJM JW Cardiol Jun 2014 and J Am Coll Cardiol 2014; 63:2438, knowledge has rapidly progressed regarding the natural history of VHD; new medications have been approved, such as the direct-acting oral anticoagulants (DOACs); and transcatheter therapies have advanced. This progress has prompted this focused update.

Key Points

The Class IIa (moderate recommendation) guideline that antibiotic …

Reviewing Author

Howard C. Herrmann, MD

Disclosures

Consultant/Advisory BoardAffluent Medical; Artedrone; Caranx; Johnson & Johnson; Medtronic; Prolifagen; Wells Fargo

EquityMicrointerventional Devices, Inc.

RoyaltiesUniversity of Pennsylvania

Grant/Research SupportAbbott Vascular; Edwards Lifesciences; Johnson & Johnson; Medtronic

Editorial BoardsCatheterization and Cardiovascular Interventions; Journal of the American College of Cardiology; Circulation: Cardiovascular Interventions; JACC Cardiovascular Interventions; JACC Case Reports; JSCAI

Leadership Positions in Professional SocietiesHeart Valve Collaboratory (Scientific Committee Member, Chair of the Publications Committee)